Exhibiting at VIV Asia 2025

Shandong Luxi Animal Medicine Share Co., Ltd., established in Qihe County, Shandong Province, is a prominent veterinary pharmaceutical manufacturer and a designated high-tech enterprise in China. With a strategic focus on anticoccidials, ectoparasiticides, growth promoters, and veterinary disinfectants, Luxi Animal Medicine has cemented its reputation as a reliable partner in global animal health and biosecurity.

Core Business and Product Portfolio

The company’s manufacturing and R&D efforts are concentrated on the development and supply of veterinary active pharmaceutical ingredients (APIs) and formulations tailored to prevent, treat, and manage infectious diseases and parasitic conditions in livestock and poultry.

Anticoccidials

• Diclazuril
• Toltrazuril
• Decoquinate
• Nicarbazin

These agents are widely used in poultry farming to control coccidiosis, a disease responsible for significant economic losses in broiler production. Luxi’s formulations are known for their consistent efficacy, compliance with residue limits, and broad-spectrum protection.

Ectoparasiticides

• Cyromazine
• Diazinon
• Amitraz

Used for the control of external parasites such as flies, ticks, and mites, these molecules support livestock welfare and reduce vector-borne disease risks in farms.

Disinfectants

• Various in-house formulated disinfectant solutions designed for high-level biosecurity applications in animal housing, equipment, and transport.

Growth Promoters and Natural Extracts

• Oregano Oil
• Garlicin

Natural compounds that support animal performance and immunity, offering alternatives to antibiotic growth promoters in compliance with global residue-free regulations.

Antibiotic Preparations

• Tylosin Tartrate and other macrolide antibiotics used to control respiratory and enteric infections in poultry and swine.

Manufacturing Infrastructure

Luxi operates modern GMP-certified manufacturing facilities that include:

• API production workshops
• Powder and granule formulation lines
• Liquid extraction and blending systems
• Packaging and logistics units

The facilities are designed to meet both domestic and international regulatory standards, with adherence to China’s Veterinary GMP guidelines and ISO quality systems.

Certifications and Regulatory Compliance

Luxi Animal Medicine is compliant with multiple quality and safety standards, ensuring product reliability and global market accessibility:

• GMP Veterinary Drug Certification – Certified by China's Ministry of Agriculture
• ISO 9001:2015 – Quality Management
• ISO 14001 – Environmental Management
• Registration of Key Products – In export markets including Southeast Asia, Middle East, Africa, and Latin America

The company’s regulatory affairs department actively supports clients in product registration and documentation for international trade.

Research and Innovation

Luxi maintains an internal R&D center led by a team of experienced pharmacists and veterinarians. The company’s research focuses on:

• Developing new anticoccidial combinations
• Resistance management strategies
• Optimization of herbal alternatives to antibiotics
• Stability and bioavailability improvements in drug formulations

The company holds several proprietary techniques in formulation stabilization and controlled release systems for long-acting veterinary therapeutics.

Global Trade and Export Data

Luxi is an established exporter with strong global partnerships across veterinary supply chains. Based on available trade data:

• International Shipments (2021–2023): Over 180 verified consignments
• Top Export Destinations: Vietnam, Egypt, Indonesia, Nigeria, Peru
• Key Exported Products: Diclazuril, Cyromazine, Tylosin Tartrate

Exports are facilitated through both direct sales and collaborative partnerships with global animal health distributors.

Target Clients and Market Applications

Luxi’s product solutions are tailored to serve:

• Commercial poultry and swine farms
• Veterinary pharmaceutical companies
• Animal health distributors and importers
• Livestock industry development projects

Its focus on preventive health, disease control, and natural growth promoters aligns with evolving regulatory trends and consumer demand for safe, residue-free animal products.

Recognitions and Achievements

• 2022: Expanded GMP-certified API facility to support growing export demand
• 2021: Received the Shandong High-Tech Enterprise Award for innovation in veterinary formulations
• 2020: Registered multiple anticoccidial products in Southeast Asia and South America
• 2019: Ranked among top 50 veterinary pharmaceutical manufacturers in China

With over two decades of experience and a growing global presence, Shandong Luxi Animal Medicine Share Co., Ltd. continues to play a vital role in safeguarding animal health through innovative, safe, and effective pharmaceutical solutions.